Platelets and Coagulation

  • Pearse Morris


Platelets play an important role in normal hemostasis by direct effects at the site of vascular injury and by indirect effects through interaction with the hemostatic cascades of circulating blood (Fig. 1.1A-D). Under abnormal circumstances, such as those related to genesis factors of atherosclerosis or factors that prevail during neurointerventional procedures, platelet function plays an important role in the pathogenesis of occlusive and thrombotic complications. Arterial thrombus is frequently described as “white thrombus” composed of densely packed platelets and fibrin. This is in contrast to the loosely packed “red thrombus” of venous thrombosis which contains a greater proportion of erythrocytes. For safe neurointerventional work within the arteries, familiarity with the currently available antiplatelet and antithrombotic drugs is necessary.


Platelet Aggregation Thrombotic Thrombocytopenic Purpura Snake Venom Activate Clotting Time Platelet Membrane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Del Zoppo GJ (1998) The role of platelets in ischemic stroke. Neurology 51: S9 - S14.PubMedCrossRefGoogle Scholar
  2. 2.
    Becker RC, Bovill EG, Seghatchian MJ, Samama MM (1998) Pathobiology of thrombin in acute coronary syndromes. Am Heart J 136: S19 - S31.PubMedCrossRefGoogle Scholar
  3. 3.
    Becker RC (1999) Thrombosis and the role of the platelet. Am J Cardiol 83: 3E - 6E.PubMedCrossRefGoogle Scholar
  4. 4.
    Droll H-I, Hellums JD, Guo Z, Durante W, Razdan K, Harbolich JK, Schafer AI (1993) Protein kinase C is activated in platelets subjected to pathological shear stress. J Biol Chem 268: 3520–3524.Google Scholar
  5. 5.
    Konstantopoulos K, Grotta JC, Sills C, Wu KK, Hellums JD (1995) Shear-induced platelet aggregation in normal subjects and stroke patients. Thrombosis and Haemostasis 74: 1329–1334.PubMedGoogle Scholar
  6. 6.
    Kamiguti AS, Hay CR, Zuzel M (1996) Inhibition of collagen-induced platelet aggregation as the result of cleavage of alpha 2 beta 1-integrin by the snake venom metalloproteinase jararhagin. Biochem J 320: 635–641.PubMedGoogle Scholar
  7. 7.
    De Luca M, Ward CM, Ohmori K, Andrews RK, Berndt MC (1995) Jararhagin and jaracetin: novel snake venom inhibitors of the integrin collagen receptor, alpha 2 beta 1. Biochem and Biophys Res Comm 206: 570–576.CrossRefGoogle Scholar
  8. 8.
    Kawasaki T, Taniuchi Y, Hisamichi N, Fujimura Y, Suzuki M, Titani K, Sakai Y, Kaku S, Satoh N, Takenaka T (1995) Tokaracetin, a new platelet antagonist that binds to platelet glycoprotein Ib and inhibits von Willebrand factor-dependent shear-induced platelet aggregation. Biochem J 308: 947–953.PubMedGoogle Scholar
  9. 9.
    Kamiguti AS, Hay CR, Theakston RD, Zuzei. M (1996) Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases. Toxicon 34: 627–642.Google Scholar
  10. 10.
    Vucxovic SA (1996) Glanzmann’s thrombasthenia revisited. J Emergency Med 14: 299–303.CrossRefGoogle Scholar
  11. 11.
    Clemetson KJ (1997) Platelet GPIb-V-IX complex. Thrombosis and Haemostasis 78: 266–270.Google Scholar
  12. 12.
    Kenny D, Morateck PA, Gill JC, Montgomery RR (1999) The critical interaction of glycoprotein (GP) Ibeta with GPIX-a genetic cause of Bernard-Soulier syndrome. Blood 93: 2968–2975.PubMedGoogle Scholar
  13. 13.
    Bithell TC, Parekh SJ, Strong RR (1972) Platelet-function studies in the Bernard-Soulier syndrome. Ann NYAcad Sci 201: 145–160.CrossRefGoogle Scholar
  14. 14.
    Kamiguti AS, Laing GD, Lowe GM, Zuzel M, Warrell DA, Theakston RD (1994) Biological properties of the venom of the Papuan black snake (Pseudechis papuanus): presence of a phospholipase A2 platelet inhibitor. Toxicon 32: 915–925.PubMedCrossRefGoogle Scholar
  15. 15.
    Anonymous (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. Br Med J 308: 81–106.CrossRefGoogle Scholar
  16. 16.
    Craven LL (1953) Experiences with aspirin (acetylsalicyclic acid) in the non-specific prophylaxis of coronary thrombosis. Mississippi Valley Med J 75: 38–40.Google Scholar
  17. 17.
    Anonymous (1978) A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Eng J Med 299: 53–59.CrossRefGoogle Scholar
  18. 18.
    Patrano C (1994) Aspirin as an antiplatelet drug. N Eng J Med 330: 1287–1294.CrossRefGoogle Scholar
  19. 19.
    Schafer AI (1996) Antiplatelet therapy. Am J Med 101: 199–209.PubMedCrossRefGoogle Scholar
  20. 20.
    Gorelick PB, Born GV, D’agostino RB, Hanley DF JR, Moye L, Pepine CJ (1999) Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Stroke 30: 1716–1721.PubMedCrossRefGoogle Scholar
  21. 21.
    Quinn MJ, Fitzgerald DJ (1999) Ticlopidine and clopidogrel. Circulation 100: 1667–1672.PubMedCrossRefGoogle Scholar
  22. 22.
    Hanky GJ, Ludlow CLM, Dunbabin DW (2000) Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 31: 1779–1784.CrossRefGoogle Scholar
  23. 23.
    Harbison JW (1992) Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 23:1723–1727.PubMedCrossRefGoogle Scholar
  24. 24.
    Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG (1989) The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1: 1215–1220.PubMedCrossRefGoogle Scholar
  25. 25.
    Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuels-Son H, Fontanelli A, Pieper M, Wesseling T, Sagnard L (1998) Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98: 2126–2132.PubMedCrossRefGoogle Scholar
  26. 26.
    Rupprecht HJ, Darius H, Borkowski U, Voigtlander T, Nowak B, Genth S, Meyer J (1998) Comparison Of an- tiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 97: 1046–1052.PubMedCrossRefGoogle Scholar
  27. 27.
    Szto GY, Linnembier TJ, Ball MW (1999) Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 83: 138–139.PubMedCrossRefGoogle Scholar
  28. 28.
    Jamar S, Vanderheyden M, Janssens L, Hermans L, Jamar R, Verstreken G (1998) Thrombotic thrombocytopenic purpura: a rare but potentially life-threatening complication following ticlopidine administration. Acta Cardiologica 53: 285–286.PubMedGoogle Scholar
  29. 29.
    Steinhubl SR, Tan WA, Foody JM, Topol EJ (1999) Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 281: 806–810.PubMedCrossRefGoogle Scholar
  30. 30.
    Chen DK, Kim JS, Sutton DM (1999) Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature. Arch Intern Med 159: 311–314.PubMedCrossRefGoogle Scholar
  31. 31.
    Anonymous (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348: 1329–1339.CrossRefGoogle Scholar
  32. 32.
    Makkar RR, Eigler NL, Kaul S, Frimerman A, Nakamura M, Shah PK, Forrester JS, Herbert JM, Litvack F (1998) Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Europ Heart J 19: 1538–1546.CrossRefGoogle Scholar
  33. 33.
    Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, Maida R, Collins M, Kreps E, Moses JW (1999) Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99: 2364–2366.PubMedCrossRefGoogle Scholar
  34. 34.
    Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, Mccarthy LJ, Sarode R, Hatfield AJ, Feld-Man MD, Davidson CJ, Tsai HM (2000) Thrombotic thrumbocytopenic purpura associated with clopidogrel. N Engl J Med 342: 1773–1777.PubMedCrossRefGoogle Scholar
  35. 35.
    Coller BS (1985) A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 76: 101–108.PubMedCrossRefGoogle Scholar
  36. 36.
    Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF (1993) Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 268: 1058–1065.PubMedGoogle Scholar
  37. 37.
    Scarborough RM, Rose JW, HSU MA, Phillips DR, Fried VA, Campbel AM, Nannizzi L, Charo IF (1991) Barbourin. A GPIIb/IIIa specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 266: 9359–9362.Google Scholar
  38. 38.
    Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, Cook JL, Niewiarowski S (1990) Disintegrins: A family of integrin inhibitory proteins from viper venoms. Proc Soc Exper Biol Med 195: 168–171.Google Scholar
  39. 39.
    Anonymous (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330: 956–961.CrossRefGoogle Scholar
  40. 40.
    Anonymous (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 336: 1689–1696.CrossRefGoogle Scholar
  41. 41.
    Anonymous (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349: 1429–1435.CrossRefGoogle Scholar
  42. 42.
    Anonymous (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 352: 87–92.Google Scholar
  43. 43.
    Anonymous (1997) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 96: 1445–1453.CrossRefGoogle Scholar
  44. 44.
    Anonymous (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 349: 1422–1428.CrossRefGoogle Scholar
  45. 45.
    Tcheng JE (1999) Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. Am J Cardiol 83: 7E - 11E.PubMedCrossRefGoogle Scholar
  46. 46.
    Giri S, Mitchel JF, Hirst JA, Mckay RG, Azar RR, Men-Nett R, Waters DD, Kiernan FJ (2000) Synergy between intracoronary stenting and Abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Cardiol 86: 269–274.PubMedCrossRefGoogle Scholar
  47. 47.
    Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neuman F, Schwaiger M (2000) Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 343: 385–391.PubMedCrossRefGoogle Scholar
  48. 48.
    Anonymous (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 338: 1498–1505.CrossRefGoogle Scholar
  49. 49.
    Anonymous (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and nonQ-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338: 1488–1497.CrossRefGoogle Scholar
  50. 50.
    Anonymous (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339: 436–443.CrossRefGoogle Scholar
  51. 51.
    Anonymous (1998) International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 97: 2386–2395.CrossRefGoogle Scholar
  52. 52.
    Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ (1998) Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/ííía receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 98: 1268–1278.PubMedCrossRefGoogle Scholar
  53. 53.
    Cannon CP, Mccabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E (1998) Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation 97: 340–349.Google Scholar
  54. 54.
    Kleiman NS (1999) Pharmacokinetics and Pharmacodynamics of Glycoprotein IIb/IIIa inhibitors. Am Heart J 138: S263 - S275.CrossRefGoogle Scholar
  55. 55.
    Coller BS (1999) Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 138: 51 - S5.CrossRefGoogle Scholar
  56. 56.
    Anonymous (1999) Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. Circulation 100: 799–806.CrossRefGoogle Scholar
  57. 57.
    Antman EM, Giugliano RP, Gibson CM, Mccabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van Der Wieken R, Ducas J, Scherer J, Anderson K, Van De Were F, Braunwald E (1999) Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 99: 2720–2732.PubMedCrossRefGoogle Scholar
  58. 58.
    Ambrose JA, Hawkey M, Badimon JJ, Coppola J, Geagea JP, Rentrop P, Domiguez A, Duvvuri S, Elmquist T, Arias J, Doss R, Dangas G (2000) In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol 86: 150–152.CrossRefGoogle Scholar
  59. 59.
    The Abciximab In Ischemic Stroke Investigators (2000) Abciximab in Acute Ischemic Stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 31: 601–609.CrossRefGoogle Scholar
  60. 60.
    Bednar B, Cook JJ, Holahan MA, Cunningham ME, Jumes PA, Bednar RA, Hartman GD, Gould RJ (1999) Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/ííía. Blood 94: 587–599.PubMedGoogle Scholar
  61. 61.
    Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kubler W, Bode C (1999) Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 84: 519–524.CrossRefGoogle Scholar
  62. 62.
    Madan M, Berkowitz SD (1999) Understanding thrombocytopenia and antigenicity with Glycoprotein IIb/IIIa inhibitors. Am Heart J 138: S317 - S326.CrossRefGoogle Scholar
  63. 63.
    Kereiakes DJ, Berkowitz SD, Lincoff AM, Tcheng JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ (2000) Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 140: 74–80.PubMedCrossRefGoogle Scholar
  64. 64.
    Jubelirer SJ, Koenig BA, Bates MC (1999) Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 61: 205–208.PubMedCrossRefGoogle Scholar
  65. 65.
    Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ (2000) Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 140: 206–211.PubMedCrossRefGoogle Scholar
  66. 66.
    Dyke CM (1999) Safety of Glycoprotein IIb/IIIa inhibitors: A Heart Surgeon’s perspective. Am Heart J 138: S307 - S316.CrossRefGoogle Scholar
  67. 67.
    Kereiakes DJ, Broderick TM, Roth EM, Whang D, Shimshak T, Runyon JP, Hattemer C, Schneider J, Lacock P, Mueller M, Abbottsmith CW (1999) Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 84: 391–395.PubMedCrossRefGoogle Scholar
  68. 68.
    Mclean J (1916) The thrombplastic action of cephalin. Am J Physiol 41: 250–257.Google Scholar
  69. 69.
    Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L (1995) Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 108 (suppl): 258S - 275S.PubMedCrossRefGoogle Scholar
  70. 70.
    Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN (2000) Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part II-Clinical aspects and recommendations. Neurosurgery 46: 1360–1376.PubMedCrossRefGoogle Scholar
  71. 71.
    Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN (2000) Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I-Pathophysiological and pharmacological features. Neurosurgery 46: 1344–1359.PubMedCrossRefGoogle Scholar
  72. 72.
    Bowers J, Ferguson JJ (1994) The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol 17: 357–361.PubMedCrossRefGoogle Scholar
  73. 73.
    Warkentin TE (1997) Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Safety 17: 325–341.PubMedCrossRefGoogle Scholar
  74. 74.
    King DJ, Kelton JG (1984) Heparin associated thrombocytopenia. Ann Intern Med 100: 535–540.PubMedGoogle Scholar
  75. 75.
    Adams HP, Leira EC (1997) Acute therapeutic intervention. Antithrombotic and antiplatelet-aggregating drugs. Neurosurgery Clinic of North America 8: 207–217.Google Scholar
  76. 76.
    Hirsh J, Fuster V (1994) Guide to Anticoagulant Therapy Part 1: Heparin. Circulation 89: 1449–1468.PubMedCrossRefGoogle Scholar
  77. 77.
    Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ (1998) Heparin-induced thrombocytopenia. JAm Coll Cardiol 31: 1449–1459.CrossRefGoogle Scholar
  78. 78.
    Ortel TL, Chong BH (1998) New treatment options for heparin-induced thrombocytopenia. Sem Hematol 35: 26–34.Google Scholar
  79. 79.
    Anonymous (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 335: 775–782.CrossRefGoogle Scholar
  80. 80.
    White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B (1997) Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 96: 2155–2161.PubMedCrossRefGoogle Scholar
  81. 81.
    Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, Van Dijk R, Van Den Bos AA, Umans VA, Fox KA (1995) A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 333: 757–763.PubMedCrossRefGoogle Scholar
  82. 82.
    Antman EM (1996) Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94: 911–921.PubMedCrossRefGoogle Scholar
  83. 83.
    Tennant SN, Dixon J, Venable TC, Page HL Jr, Roach A, Kaiser AB, Frederiksen R, Tacogue L, Kaplan P, Babu NS (1984) Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase. Circulation 69: 756–760.PubMedCrossRefGoogle Scholar
  84. 84.
    Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Row-Ley HA, Gent M (1998) PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 29: 4–11.PubMedCrossRefGoogle Scholar
  85. 85.
    Van Griensven JM, Koster RW, Burggraaf J, Huisman LG, Kluft C, Kroon R, Schoemaker RC, Cohen AF (1998) Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction. Clin Pharmacol Ther 63: 39–47.PubMedCrossRefGoogle Scholar
  86. 86.
    Cannon CP, Mccabe CH, Gibson CM, Ghali M, Sequeira RF, Mckendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E (1997) TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 95: 351–356.PubMedCrossRefGoogle Scholar
  87. 87.
    Qureshi AI, Suri FK, Shatla AA, Ringer AJ, Fessler RD, Au Z, Guterman LR, Hopkins LN (2000) Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen. Neurosurgery 47: 473–479.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Pearse Morris
    • 1
  1. 1.School of MedicineWake Forest UniversityWinston-SalemUSA

Personalised recommendations